WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 401562
Description: NVP-BEP800, also known as BEP-800, is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Hsp90. NVP-BEP800 showed activity against a panel of human tumor cell lines and primary human xenografts in vitro at nanomolar concentrations. In A375 melanoma and BT-474 breast cancer cell lines, NVP-BEP800 induced client protein degradation (including ErbB2, B-Raf(V600E), Raf-1, and Akt) and Hsp70 induction.
MedKoo Cat#: 401562
Chemical Formula: C21H23Cl2N5O2S
Exact Mass: 479.09495
Molecular Weight: 480.41062
Elemental Analysis: C21H23Cl2N5O2S
NVP-BEP800, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: NVP BEP800; NVP-BEP 800; NVP BEP-800; BEP-800; BEP800; BEP 800.
IUPAC/Chemical Name: 2-amino-4-(2,4-dichloro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
InChi Key: WJUNQSYQHHIVFX-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H23Cl2N5O2S/c1-2-25-19(29)17-10-13-18(26-21(24)27-20(13)31-17)12-9-16(15(23)11-14(12)22)30-8-7-28-5-3-4-6-28/h9-11H,2-8H2,1H3,(H,25,29)(H2,24,26,27)
SMILES Code: O=C(C1=CC2=C(C3=CC(OCCN4CCCC4)=C(Cl)C=C3Cl)N=C(N)N=C2S1)NCC
The following data is based on the product molecular weight 480.41062 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Stingl L, StÃ¼hmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer. 2010 May 25;102(11):1578-91. PubMed PMID: 20502461; PubMed Central PMCID: PMC2883148.
2: Massey AJ, Schoepfer J, Brough PA, Brueggen J, ChÃ¨ne P, Drysdale MJ, Pfaar U, Radimerski T, Ruetz S, Schweitzer A, Wood M, Garcia-Echeverria C, Jensen MR. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther. 2010 Apr;9(4):906-19. Epub 2010 Apr 6. PubMed PMID: 20371713.
3: StÃ¼hmer T, Chatterjee M, Grella E, Seggewiss R, Langer C, MÃ¼ller S, Schoepfer J, Garcia-Echeverria C, Quadt C, Jensen MR, Einsele H, Bargou RC. Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800. Br J Haematol. 2009 Nov;147(3):319-27. Epub 2009 Aug 13. PubMed PMID: 19686236.